The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery—a Retrospective Analysis

• DOI: 10.1007/s11695-022-06211-9
• Publication Date: 2022-07-25T19:02:52Z
• Authors: Anne Lautenbach; Marie Wernecke; Tobias B. Huber; Fabian Stoll; Jonas Wagner; Sebastian M. Meyh...; Svenja Meyhöfer; Jens Aberle
• Keywords: Semaglutide; Clinical endpoint

Abstract Purpose About 20–25% of patients experience weight regain (WR) or insufficient loss (IWL) after bariatric metabolic surgery (BS). Therefore, we aimed to retrospectively assess the effectiveness adjunct treatment with GLP-1 receptor agonist semaglutide in non-diabetic WR IWL BS. Materials and Methods Post-bariatric without type 2 diabetes (T2D) ( n = 44) were included analysis. The primary endpoint was 3 6 months initiation treatment. Secondary endpoints change BMI, HbA1c, lipid profile, hs-CRP, liver enzymes. Results Patients started 64.7 ± 47.6 (mean SD) At semaglutide, post-bariatric nadir 12.3 14.4% SD). Total during − 6.0 4.3% SD, p < 0.001) (3.2 months, IQR 3.0–3.5, 38) 10.3 5.5% (5.8 5.8–6.4, 20). categorical > 5% 61% patients, 10% 16% 15% 2% patients. Triglycerides (OR 0.99; 0.05), ALT 0.87; AST 0.89; 0.05) at baseline negatively associated least months’ follow-up 0.05). Conclusion Treatment options manage excess (regain) are scarce. Our results imply a clear benefit However, these need be confirmed prospective randomized controlled trial close gap between lifestyle intervention revision Graphical abstract